CYP2D6 genes and risk of liver cancer
- 1 April 1995
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 345 (8953), 830-831
- https://doi.org/10.1016/s0140-6736(95)92965-7
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibilityCarcinogenesis: Integrative Cancer Research, 1992
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles ofCYP2D6in a European PopulationDNA and Cell Biology, 1991
- Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidencePharmacogenetics, 1991
- A tobacco smoke-derived nitrosamine, 4-(methytnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytocbrome P450s including the polymorphic human cytochrome P4502D6Carcinogenesis: Integrative Cancer Research, 1991
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1.Proceedings of the National Academy of Sciences of the United States of America, 1990